YMAT vs ABEO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABEO Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abeona Therapeutics Inc. Common Stock (ABEO) driven by superior Valuation, Growth & Margin, Options & Structure while YMAT counters with relative strength in Momentum & Technical. Fundamentally, YMAT trades at N/M Forward P/E with -372.2% operating margin (-36.1% YoY revenue) versus ABEO at 18.7x Forward P/E and -186.1% operating margin (+2745.0% YoY). In options structure, YMAT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ABEO sits in BREAKDOWN (27th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | YMAT | ABEO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.8M | $149.2M | Larger Scale | ABEO |
| Trailing P/E Ratio Valuation | N/M | 18.7x | Lower Multiple | ABEO |
| Forward P/E Ratio Valuation | N/M | 18.7x | Lower Multiple | ABEO |
| Revenue Growth (YoY) Growth | -36.1% | +2745.0% | Higher Growth | ABEO |
| Operating Margin (TTM) Profitability | -372.2% | -186.1% | Higher Margin | ABEO |
| Net Profit Margin Profitability | 0.0% | -160.3% | Higher Margin | YMAT |
| Return on Equity (ROE) Capital Efficiency | -275.9% | -42.1% | Higher ROE | ABEO |
| 52-Week Range Position Momentum | 15% ($0โ$4) | 9% ($2โ$8) | Stronger Trend | YMAT |
| Beta / 30D Volatility Risk Regime | 5.73ฮฒ ยท 218% Vol | 0.60ฮฒ ยท 149% Vol | Lower Realized Risk | ABEO |
| Unified Institutional Score Composite Signal | 57.8 / 100 (HOLD) | 44.9 / 100 (HOLD) | Higher Composite | YMAT |